No Data
ANTENGENE-B (06996.HK) plans to hold a Board of Directors meeting on March 21 to approve the annual performance.
Gelonghui reported on March 11 that ANTENGENE-B (06996.HK) announced that the Board of Directors will hold a meeting on March 21, 2025 (Friday) to consider and approve the performance of the company and its subsidiaries for the fiscal year ending December 31, 2024 and its release.
ANTENGENE-B: NOTICE OF DATE OF BOARD MEETING
National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two
① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.
The investment secrets in the government work report: Analyzing the collaborative logic of the Global Strategy and policies of Guoshengtang (2273.HK).
The report clearly states to strengthen basic Medical and health services.
Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%
ANTENGENE-B (06996.HK): The new drug application for Xiwiao has been approved by the Indonesian Food and Drug Authority.
Gelonghui, March 5 - ANTENGENE-B (06996.HK) announced that the Indonesian Food and Drug Authority (BPOM) has approved the new drug application (NDA) for Cevio (Selinexor tablets) for three indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior treatment; (2) in combination with dexamethasone for the treatment of patients who have received at least four prior treatments and are resistant to at least two proteasome inhibitors (PI), at least two immunomodulatory drugs (IMiD), and one anti-CD38 monoclonal antibody.
